PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Molecular Profiling Predicts First Site of Recurrence in Pancreatic Cancer After Neoadjuvant Therapy

Abstract 6446: Molecular profiling to predict the first site of recurrence in pancreatic cancer patients receiving neoadjuvant therapy followed by surgery

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLuigi LiguoriMVMarco VentinLZLiti Zhang

Discussion

Loading...

Member takes

Overview

Retrospective analysis predicts recurrence site in pancreatic cancer, suggesting targeted surveillance strategies.

Key Points

  • The research aims to identify molecular biomarkers that predict recurrence patterns in pancreatic ductal adenocarcinoma patients after neoadjuvant therapy and surgery.
  • Retrospective analysis of PDAC patients who received neoadjuvant therapy followed by surgery
  • Utilization of uni- and multivariable binary logistic regression
  • Assessment of clinicopathologic variables and NGS-based molecular features
  • Analysis of recurrence patterns across a cohort of 244 patients
  • Mutations in KRASQ61X, CDKN2B, ATM, and BRCA2 were significantly associated with specific recurrence sites
  • Locoregional recurrence linked to KRASQ61X mutation (OR, 5.6)
  • Liver recurrence associated with CDKN2B mutations (OR, 4.4)
  • ATM mutations correlated with lung and peritoneal recurrences (ORs, 7.7 and 5.0 respectively)
  • Bone recurrence predicted by BRCA2 mutations (OR, 7.7)

Cite This Study

Liguori et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdf7a79560c99a0a4525https://doi.org/10.1158/1538-7445.am2026-6446
View Full Paper
Ask AI
Bookmark
Share